Research programme: KIBRA modulators - SYGNIS Pharma

Drug Profile

Research programme: KIBRA modulators - SYGNIS Pharma

Latest Information Update: 27 Dec 2012

Price : $50

At a glance

  • Originator Amnestix
  • Developer SYGNIS Pharma
  • Class Peptides
  • Mechanism of Action Intracellular signalling peptide and protein modulators; Phosphoprotein modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Alzheimer's disease; Cognition disorders

Most Recent Events

  • 20 Dec 2012 Discontinued for Alzheimer's disease in Germany (unspecified route)
  • 20 Dec 2012 Discontinued for Cognition disorders in Germany (unspecified route)
  • 25 Jul 2012 SYGNIS Pharma is seeking partnering opportunities for the development of its KIBRA modulators programme. http://www.sygnis.de/
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top